Member Info for tombi1

anybody have any sensible ideas why board have kept brian ,what could they have lined up for him , or is he todays rns

On this occasion definitely and the market agreed

Jp should go Into politics .He cannot do any harm there. Do lot of talking then do nothing .seems apt

First rns we have for a long time where the market likes it

Where is hawky and his gang

They must have been buying all that came up , wonder what hawky thinks

Time to do the decent thing

look out for more trading either way which will give us an idea , this close to results

that should say

i see the market is impressed with our great deal maker

thanks eric still very poor l2 , a lot of sellers still out there

the sound board have caused this sell off they need to explain themselves

Sitting on the fence has put us in this position time for action

If we wait it could be to late and it will be over with the option of not going back , they should never released such a poor rns with main details missing , knowing it would crash the price , they have to be accountable

Hi. All add my name

17,m cap with a 4 well drill programme ,,,,,

everybody just waiting

ve reread this from the previous RNS ,it looks like they are doing more than they need to to get this over the line , it does seem to come over with great confidence

A 12-month open-label extension study to assess long-term safety and tolerability of a drug is a standard regulatory requirement for drugs intended for long-term treatment of non-life-threatening conditions, such as ED. In line with advice received from regulatory authorities, Futura has designed an OLE in which subjects recruited from primarily high patient volume countries are invited to enter into the OLE on the 0.6% dose a few days after completing the double-blind phase and follow up visit of FM57. In OLE studies, generally 300 to 600 patients are evaluated for 6 months and at least 100 of those patients for 12 months; defined by the International Conference on Harmonisation (ICH) guideline E1. Therefore, to meet this requirement, Futura are pleased to announce that 450 subjects from the double-blind phase of FM57 have agreed to enter the OLE study. As previously reported on 11 September 2019 interest in patients electing to enter the OLE remained high having completed the double-blind phase of FM57.

anyone know how long the results usually take i know they said december but is it possible before that

might be a good idea for parsons to step down here and echo to give them both a fighting chance he has enough on his plate at sound

yes is there any timelines at sidi so we don't lose licence